0
Get Alert
Please Wait... Processing your request... Please Wait.
You must sign in to sign-up for alerts.

Please confirm that your email address is correct, so you can successfully receive this alert.

1
INFLUENTIAL PUBLICATIONS   |    
Bibliography for Major Depressive Disorder and Suicide
FOCUS 2008;6:58-62.

This section contains a compilation of recent publications that have shaped the thinking in the field as well as classic works that remain important to the subject reviewed in this issue. This bibliography has been compiled by experts in the field and members of the editorial and advisory boards. Entries are listed chronologically and within years by first author. Articles from the bibliography that are reprinted in this issue are in bold type.

Abstract Teaser
Figures in this Article

Irwin MR, Miller AH: Depressive disorders and immunity: 20 years of progress and discovery.  Brain Behav Immun 2007; 21: 374— 383
[PubMed]
[CrossRef]
 
Duman RS, Monteggia LM: A neurotrophic model for stress-related mood disorders.  Biol Psychiatry 2006; 59: 1116— 1127
[PubMed]
[CrossRef]
 
Merali Z, Du L, Hrdina P, Palkovits M, Faludi G, Poulter MO, Anisman H. Dysregulation in the suicide brain: mRNA expression of corticotropin-releasing hormone receptors and GABA(A) receptor subunits in frontal cortical brain region.  J Neurosci . 2004  2 11; 24( 6): 1478— 85. Free text at http://www.jneurosci.org/cgi/content/full/24/6/1478
[PubMed]
[CrossRef]
 
Vythilingam M, Heim C, Newport J, Miller AH, Anderson E, Bronen R, Brummer M, Staib L, Vermetten E, Charney DS, Nemeroff CB, Bremner JD: Childhood trauma associated with smaller hippocampal volume in women with major depression.  Am J Psychiatry 2002; 159: 2072— 2080
[PubMed]
[CrossRef]
 
Klimek V, Schenck JE, Han H, Stockmeier CA, Ordway GA. Dopaminergic abnormalities in amygdaloid nuclei in major depression: a postmortem study.  Biol Psychiatry . 2002  10 1; 52( 7): 740— 8.
[PubMed]
[CrossRef]
 
Hindmarch I: Expanding the horizons of depression: beyond the monoamine hypothesis.  Hum Psychopharmacol 2001; 16: 203— 218
[PubMed]
[CrossRef]
 
Manji HK, Duman RS: Impairments of neuroplasticity and cellular resilience in severe mood disorders: implications for the development of novel therapeutics.  Psychopharmacol Bull 2001; 35: 5— 49
 
McEwen BS, Magarinos AM: Stress and hippocampal plasticity: implications for the pathophysiology of affective disorders.  Hum Psychopharmacol 2001; 16: S7— S19
[PubMed]
[CrossRef]
 
Sapolsky RM: The possibility of neurotoxicity in the hippocampus in major depression: a primer on neuron death.  Biol Psychiatry 2000; 48: 755— 765
[PubMed]
[CrossRef]
 
Moreno FA, Gelenberg AJ, Heninger GR, Potter RL, McKnight KM, Allen J, Phillips AP, Delgado PL: Tryptophan depletion and depressive vulnerability.  Biol Psychiatry 1999; 46: 498— 505
[PubMed]
[CrossRef]
 
Mayberg HS, Liotti M, Brannan SK, McGinnis S, Mahurin RK, Jerabek PA, Silva JA, Tekell JL, Martin CC, Lancaster JL, Fox PT. Reciprocal limbic-cortical function and negative mood: converging PET findings in depression and normal sadness.  Am J Psychiatry . 1999  5; 156( 5): 675— 82.
[PubMed]
 
Musselman DL, Tomer A, Manatunga AK, Knight BT, Porter MR, Kasey S, Marzec U, Harker LA, Nemeroff CB. Exaggerated platelet reactivity in major depression.  Am J Psychiatry . 1996  10; 153( 10): 1313— 7.
[PubMed]
 
Coplan JD, Andrews W, Rosenblum LA, Owens MJ, Friedman S, Gorman JM, Nemeroff CB. Persistent elevations of cerebrospinal fluid concentrations of corticotropin-releasing factor in adult nonhuman primates exposed to early-life stressors: implications for the pathophysiology of mood and anxiety disorders.  Proc Natl Acad Sci USA . 1996  2 20; 93( 4): 1619— 23. Free text at http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pubmed&pubmedid=8643680
[PubMed]
[CrossRef]
 
DeBellis MD, Gold PW, Geracioti TD, Listwak SJ, Kling MA. Association of fluoxetine treatment with reductions in CSF concentrations of corticotropin-releasing hormone and arginine vasopressin in patients with major depression.  Am J Psychiatry 1993150: 656— 657
 
Nemeroff CB, Widerlöv E, Bissette G, Walléus H, Karlsson I, Eklund K, Kilts CD, Loosen PT, Vale W. Elevated concentrations of CSF corticotropin-releasing factor-like immunoreactivity in depressed patients.  Science . 1984  10 14; 226( 4680): 1342— 4.
[PubMed]
[CrossRef]
 
Checkley SA, Slade AP, Shur E. Growth hormone and other responses to clonidine in patients with endogenous depression.  Br J Psychiatry . 1981  1; 138: 51— 5.
 
References Container
Laje G, Paddock S, Manji H, Rush AJ, Wilson AF, Charney D, McMahon FJ: Genetic markers of suicidal ideation emerging during citalopram treatment of major depression.  Am J Psychiatry 2007; 164: 1530— 1538
[PubMed]
[CrossRef]
 
Hariri AR, Brown SM: Serotonin.  Am J Psychiatry 2006; 163: 12
[PubMed]
[CrossRef]
 
Kaufman J, Yang BZ, Douglas-Palumberi H, Grasso D, Lipschitz D, Houshyar S, Krystal JH, Gelernter J: Brain-derived neurotrophic factor-5-HTTLPR gene interactions and environmental modifiers of depression in children.  Biol Psychiatry 2007; 59: 673— 680
 
Kendler KS, Gatz M, Gardner CO, Pedersen NL: A Swedish national twin study of lifetime major depression.  Am J Psychiatry 2006; 163: 109— 114
[PubMed]
[CrossRef]
 
Kendler KS, Gardner CO, Prescott CA: Toward a comprehensive developmental model for major depression in men.  Am J Psychiatry 2006; 163: 115— 124
[PubMed]
[CrossRef]
 
McMahon FJ, Buervenich S, Charney D, Lipsky R, Rush AJ, Wilson AF, Sorant AJ, Papanicolaou GJ, Laje G, Fava M, Trivedi MH, Wisniewski SR, Manji H: Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment.  Am J Hum Genet 2006; 78: 804— 814
[PubMed]
[CrossRef]
 
Wilhelm K, Mitchell PB, Niven H, Finch A, Wedgwood L, Scimone A, Blair IP, Parker G, Schofield PR: Life events, first depression onset and the serotonin transporter gene.  Br J Psychiatry 2006; 188: 210— 215
[PubMed]
[CrossRef]
 
Gillespie NA, Whitfield JB, Williams B, Heath AC, Martin NG: The relationship between stressful life events, the serotonin transporter (5-HTTLPR) genotype and major depression.  Psychol Med 2005; 35: 101— 111
[PubMed]
[CrossRef]
 
Hariri AR, Drabant EM, Munoz KE, Kolachana BS, Mattay VS, Egan MF, Weinberger DR: A susceptibility gene for affective disorders and the response of the human amygdala.  Arch Gen Psychiatry 2005; 62: 146— 152
[PubMed]
[CrossRef]
 
Kendler KS, Kuhn JW, Vittum J, Prescott CA, Riley B: The interaction of stressful life events and a serotonin transporter polymorphism in the prediction of episodes of major depression—a replication.  Arch Gen Psychiatry 2005; 62: 529— 535
[PubMed]
[CrossRef]
 
Pezawas L, Meyer-Lindenberg A, Drabant EM, Verchinski BA, Munoz KE, Kolachana BS, Egan MF, Mattay VS, Hariri AR, Weinberger DR: 5-HTTLPR polymorphism impacts human cingulate-amygdala interactions: a genetic susceptibility mechanism for depression.  Nat Neurosci 2005; 8: 828— 834
[PubMed]
[CrossRef]
 
Weissman M, Wickramaratne P, Nomura Y, Warner V, Verdeli H, Pilowsky DJ, Grillon C, Bruder G: Families at high and low risk for depression—a 3-generation study.  Arch Gen Psychiatry 2005; 62: 29— 36
[PubMed]
[CrossRef]
 
Caspi A, Sugden K, Moffitt TE, Taylor A, Craig IW, Harrington H, McClay J, Mill J, MartinJ, Braithwaite A, Poulton R: Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene.  Science 2003; 301: 291— 293[Focus 2005; 3:156—160]
[PubMed]
 
Duman RS, Heninger GR, Nestler EJ: A molecular and cellular theory of depression.  Arch Gen Psychiatry 1997; 54: 597— 606
[PubMed]
 
References Container
Frank E, Kupfer DJ, Buysse DJ, Swartz HA, Pilkonis PA, Houck PR, Rucci P, Novick DM, Grochocinski VJ, Stapf DM: Randomized trial of weekly, twice-monthly, and monthly interpersonal psychotherapy as maintenance treatment for women with recurrent depression.  Am J Psychiatry 2007; 164: 761— 767
[PubMed]
[CrossRef]
 
Elkin I, Falconnier L, Martinovich Z, Mahoney C: Therapist effects in the National Institute of Mental Health Treatment of Depression Collaborative Research Program.  Psychother Res 2006; 16: 144— 160
[CrossRef]
 
Kim DM, Wampold BE, Bolt DM: Therapist effects in psychotherapy: a random-effects modeling of the National Institute of Mental Health Treatment of Depression Collaborative Research Program data.  Psychother Res 2006; 16: 161— 172
[CrossRef]
 
Beck AT: The current status of cognitive therapy: a 40-year retrospective.  Arch Gen Psychiatry 62: 953— 959, 2005
[PubMed]
[CrossRef]
 
Klein DN, Santiago NJ, Vivian D, Blalock JA, Kocsis JH, Markowitz JC, McCullough JP Jr, Rush AJ, Trivedi MH, Arnow BA, Dunner DL, Manber R, Rothbaum B, Thase ME, Keitner GI, Miller IW, Keller MB: Cognitive-behavioral analysis system of psychotherapy as a maintenance treatment for chronic depression.  J Consult Clin Psychol 2004; 72: 681— 688
[PubMed]
[CrossRef]
 
Berman RM, Marcus RN, Swanink R, McQuade RD, Carson WH, Corey-Lisle PK, Khan A: The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: A multicenter, randomized, double-blind placebo-controlled study.  J Clin Psychiatry 2007; 68: 843— 853
[PubMed]
[CrossRef]
 
McGrath PJ, Stewart JW, Quitkin FM, Chen Y, Alpert JE, Nierenberg AA, Fava M, Cheng J, Petkova E: Predictors of relapse in a prospective study of fluoxetine treatment of major depression.  Am J Psychiatry 2006; 163: 1542— 1548
[PubMed]
[CrossRef]
 
Olfson M, Marcus SC, Tedeschi M, Wan GJ: Continuity of antidepressant treatment for adults with depression in the United States.  Am J Psychiatry 2006; 163: 101— 108
[PubMed]
[CrossRef]
 
Rapaport MH, Gharabawi GM, Canuso CM, Mahmoud RA, Keller MB, Bossie CA, Turkoz I, Lasser RA, Loescher A, Bouhours P, Dunbar F, Nemeroff CB: Effects of risperidone augmentation in patients with treatment-resistant depression: results of open-label treatment followed by double-blind continuation.  Neuropsychopharmacology 2006; 31: 2505— 2513
[PubMed]
[CrossRef]
 
Ruhé HG, Huyser J, Swinkels JA, Schene AH: Switching antidepressants after a first selective serotonin reuptake inhibitor in major depressive disorder: A systematic review.  J Clin Psychiatry 2006; 67: 1836— 1855
[PubMed]
[CrossRef]
 
Thase ME: The failure of evidence-based medicine to guide treatment of antidepressant nonresponders.  J Clin Psychiatry 2006; 67: 1833— 1835
[PubMed]
[CrossRef]
 
Quitkin FM, McGrath PJ, Stewart JW, Deliyannides D, Taylor BP, Davies CA, Klein DF: Remission rates with 3 consecutive antidepressant trials: effectiveness for depressed outpatients.  J Clin Psychiatry 2005; 66: 670— 676
[PubMed]
[CrossRef]
 
Leichsenring F, Rabung S, Leibing E: The efficacy of short-term psychodynamic psychotherapy in specific psychiatric disorders.  Arch Gen Psychiatry 2004; 61: 1208— 1216
[PubMed]
[CrossRef]
 
Kennedy SH, Konarski JZ, Segal ZV, Lau MA, Bieling PJ, McIntyre RS, Mayberg HS: Differences in brain glucose metabolism between responders to CBT and venlafaxine in a 16-week randomized controlled trial.  Am J Psychiatry 2007; 164: 778— 788
[PubMed]
[CrossRef]
 
Zisook S, Lesser I, Stewart JW, Wisniewski SR, Balasubramani GK, Fava M, Gilmer WS, Dresselhaus TR, Thase ME, Nierenberg AA, Trivedi MH, Rush AJ: Effect of age at onset on the course of major depressive disorder.  Am J Psychiatry 2007; 164: 1539— 1546
[PubMed]
[CrossRef]
 
Dimidjian S, Hollon SD, Dobson KS, Schmaling KB, Kohlenberg RJ, Addis ME, Gallop R, McGlinchey JB, Markley DK, Gollan JK, Atkins DC, Dunner DL, Jacobson NS: Randomized trial of behavioral activation, cognitive therapy, and antidepressant medication in the acute treatment of adults with major depression.  J Consult Clin Psychol 2006; 74: 658— 670
[PubMed]
[CrossRef]
 
Markowitz JC, Kocsis JH, Bleiberg KL, Christos PJ, Sacks M: A comparative trial of psychotherapy and pharmacotherapy for "pure" dysthymic patients.  J Affect Disord 2005; 89: 167— 175
[PubMed]
[CrossRef]
 
March JS, Silva S, Petrycki S, Curry J, Wells K, Fairbank J, Burns B, Domino M, McNulty S, Vitiello B, Severe J: The Treatment for Adolescents With Depression Study (TADS): long-term effectiveness and safety outcomes.  Arch Gen Psychiatry 2007; 64: 1132— 1143
[PubMed]
[CrossRef]
 
Derubeis RJ, Hollon SD, Amsterdam JD, Shelton RC, Young PR, Salomon RM, O'Reardon JP, Lovett ML, Gladis MM, Brown LL, Gallop R: Cognitive therapy vs medications in the treatment of moderate to severe depression.  Arch Gen Psychiatry 2005; 62: 409— 416
[PubMed]
[CrossRef]
 
Fochtmann L, Gelenberg AJ: Guideline watch: practice guideline for the treatment of patients with major depressive disorder, 2nd edition.  Focus 2005; 3: 34— 42
 
Linde K, Berner M, Egger M, Mulrow C: St John's wort for depression—meta-analysis of randomised controlled trials.  Br J Psychiatry 2005; 186: 99— 107
[PubMed]
[CrossRef]
 
Keller MB, McCullough JP, Klein DN, Arnow B, Dunner DL, Gelenberg AJ, Markowitz JC, Nemeroff CB, Russell JM, Thase ME, Trivedi MH, Zajecka J: A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression.  N Engl J Med 2000; 342: 1462— 1470
[PubMed]
[CrossRef]
 
References Container
Thase ME, Friedman ES, Biggs MM, Wisniewski SR, Trivedi MH, Luther JF, Fava M, Nierenberg AA, McGrath PJ, Warden D, Niederehe G, Hollon SD, Rush AJ: Cognitive therapy versus medication in augmentation and switch strategies as second-step treatments: a STAR*D report.  Am J Psychiatry 2007; 164: 739— 752
[PubMed]
[CrossRef]
 
Wisniewski SR, Fava M, Trivedi MH, Thase ME, Warden D, Niederehe G, Friedman ES, Biggs MM, Sackeim HA, Shores-Wilson K, McGrath PJ, Lavori PW, Miyahara S, Rush AJ: Acceptability of second-step treatments to depressed outpatients: a STAR*D report.  Am J Psychiatry 2007; 164: 753— 760
[PubMed]
[CrossRef]
 
McGrath PJ, Stewart JW, Fava M, Trivedi MH, Wisniewski SR, Nierenberg AA, Thase ME, Davis L, Biggs MM, Shores-Wilson K, Luther JF, Niederehe G, Warden D, Rush AJ, Star*D Trial Team: Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medications trials for depression: A STAR*D report.  Am J Psychiatry 2006; 163: 1531— 1541
[PubMed]
[CrossRef]
 
Nierenberg AA, Fava M, Trivedi MH, Wisniewski SR, Thase ME, McGrath PJ, Alpert JE, Warden D, Luther JF, Niederehe G, Lebowitz B, Shores-Wison K, Rush AJ: A comparison of lithium and T3 augmentation following two failed medication treatments for depression: A STAR*D report.  Am J Psychiatry 2006; 163: 1519— 1530
[PubMed]
[CrossRef]
 
Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, Niederehe G, Thase ME, Lavori PW, Lebowitz BD, McGrath PJ, Rosenbaum JF, Sackeim HA, Kupfer DJ, Luther J, Fava M: Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a Star*D report.  Am J Psychiatry 2006; 163: 1905— 1917
[PubMed]
[CrossRef]
 
Rush AJ, Trivedi MH, Wisniewski SR, Stewart JW, Nierenberg AA, Thase ME, Ritz L, Biggs M, Warden D, Luther JF, Shores-Wilson K, Niederehe G, Fava M, STAR*D Study Team: Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression.  N Engl J Med 2006; 354: 1231— 1242
[PubMed]
[CrossRef]
 
Trivedi MH, Fava M, Wisniewski SR, Thase ME, Quitkin F, Warden D, Ritz L, Nierenberg AA, Lebowitz BD, Biggs MM, Luther JF, Shores-Wilson K, Rush AJ, Star*D Study Team: Medication augmentation after the failure of SSRIs for depression.  N Engl J Med 2006; 354: 1243— 1252
[PubMed]
[CrossRef]
 
Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, Norquist G, Howland RH, Lebowitz B, Mcgrath PJ, Shores-Wilson K, Biggs MM, Balasubramani GK, Fava M, Star*D Study Team: Evaluation of outcomes with citalopram for depression using measurement-based care in Star*D: implications for clinical practice.  Am J Psychiatry 2006; 163: 28— 40
[PubMed]
[CrossRef]
 
Weissman MM, Pilowsky DJ, Wickramaratne PJ, Talati A, Wisniewski SR, Fava M, Hughes CW, Garber J, Malloy E, King CA, Cerda G, Sood AB, Alpert JE, Trivedi MH, Rush AJ, STAR*D-Child Team: Remissions in maternal depression and child psychopathology: a STAR*D-child report.  JAMA 2006; 295: 1389— 1398
[PubMed]
[CrossRef]
 
Fava M, Rush AJ, Wisneiweski SR, Nierenberg AA, Alpert JE, McGrath PJ, Thase ME, Warden D, Biggs M, Luther JF, Niederehe G, Ritz L, Trivedi MH: A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: a STAR*D report.  Am J Psychiatry 2006; 163: 1521— 1541
 
References Container
Brent D: Antidepressants and suicidal behavior: cause or cure?  Am J Psychiatry 2007; 164: 989— 991
[PubMed]
[CrossRef]
 
Posner K, Oquendo MA, Gould M, Stanley B, Davies M: Columbia Classification Algorithm of Suicide Assessment (C-CASA): classification of suicidal events in the FDA's pediatric suicidal risk analysis of antidepressants.  Am J Psychiatry 2007; 164: 1035— 1043
[PubMed]
[CrossRef]
 
Sakinofsky I: Suicidality in depressive illness. Part I: current controversies.  Can J Psychiatry 2007; 52( 6Suppl 1): 71S— 84S. Available online at http://publications.cpa-apc.org/media.php?mid=425
[PubMed]
 
Simon GE, Savarino J: Suicide attempts among patients starting depression treatment with medications or psychotherapy.  Am J Psychiatry 2007; 164: 1029— 1034.
 
Szanto K, Mulsant BH, Houck PR, Dew MA, Dombrovski A, Pollock BG, Reynolds CF 3rd: Emergence, persistence, and resolution of suicidal ideation during treatment of depression in old age.  J Affect Disord 2007; 98: 153— 161
[PubMed]
[CrossRef]
 
Isacsson J: Depression is the core of suicidality—its treatment is the cure.  Acta Psychiatr Scand 2006; 114: 149— 150
[PubMed]
[CrossRef]
 
Gibbons RD, Hur K, Bhaumik KL, Mann J: The relationship between antidepressant medication use and rate of suicide.  Arch Gen Psychiatry 2005; 62: 165— 171
[PubMed]
[CrossRef]
 
Mann J, Apter A, Bertolote J, Beautrais A, Currier D, Haas A, Hegerl U, Lonnqvist J, Malone K, Marusic A, Mehlum L, Patton G, Phillips M, Rutz W, Rihmer Z, Schmidtke A, Shaffer D, Silverman M, Takahashi Y, Varnik A, Wasserman D, Yip P, Hendin H: Suicide prevention strategies: a systematic review.  JAMA 2005; 294: 2064— 2074
[PubMed]
[CrossRef]
 
Martinez C, Rietbrock S, Wise L, Ashby D, Chick J, Moseley J, Evans S, Gunnell D: Antidepressant treatment and the risk of fatal and non-fatal self harm in first episode depression: nested case-control study.  Br Med J 2005; 330: 389— 393
[CrossRef]
 
References Container
Fenton L, Fasula M, Ostroff, R, Sanacora G: Can cognitive behavioral therapy reduce relapse rates of depression after ECT? A preliminary study.  J ECT 2006; 22: 196— 198
[PubMed]
[CrossRef]
 
Couturier JL: Efficacy of rapid-rate repetitive transcranial magnetic stimulation in the treatment of depression: a systematic review and meta-analysis.  J Psychiatry Neurosci 2005; 30: 83— 90
[PubMed]
 
Dunn AL, Trivedi MH, Kampert JB, Clark CG, Chambliss HO: Exercise treatment for depression—efficacy and dose response.  Am J Prev Med 2005; 28: 1— 8
 
Rush AJ, Marangell LB, Sackeim HA, George MS, Brannan SK, Davis SM, Howland R, Kling MA, Rittberg BR, Burke WJ, Rapaport MH, Zajecka J, Nierenberg AA, Husain MM, Ginsberg D, Cooke RG: Vagus nerve stimulation for treatment-resistant depression: a randomized, controlled acute phase trial.  Biol Psychiatry 2005; 58: 347— 354
[PubMed]
[CrossRef]
 
Rush AJ, Sackeim HA, Marangell LB, George MS, Brannan SK, Davis SM, Lavori P, Howland R, Kling MA, Rittberg B, Carpenter L, Ninan P, Moreno F, Schwartz T, Conway C, Burke M, Barry JJ: Effects of 12 months of vagus nerve stimulation in treatment-resistant depression: a naturalistic study.  Biol Psychiatry 2005; 58: 355— 363
[PubMed]
[CrossRef]
 
Mayberg HS, Lozano AM, Voon V, Mcneely HE, Seminowicz D, Hamani C, Schwalb JM, Kennedy SH: Deep brain stimulation for treatment-resistant depression.  Neuron 2005; 45: 651— 660
[PubMed]
[CrossRef]
 
Pagnin D, de Queiroz V, Pini S, Cassano GB: Efficacy of ECT in depression: a meta-analytic review.  J ECT 2004; 20: 13— 20
[PubMed]
[CrossRef]
 
Kho KH, van Vreeswijk MF, Simpson S, Zwinderman AH: A meta-analysis of electroconvulsive therapy efficacy in depression.  J ECT 2003; 19: 139— 147
[PubMed]
[CrossRef]
 
References Container
Dew MA, Whyte EM, Lenze EJ, Houck PR, Mulsant BH, Pollock BG, Stack JA, Bensasi S, Reynolds CF: Recovery from major depression in older adults receiving augmentation of antidepressant pharmacotherapy.  Am J Psychiatry 2007; 164: 892— 899
[PubMed]
[CrossRef]
 
Reynolds CF 3rd, Dew MA, Pollock BG, Mulsant BH, Frank E, Miller MD, Houck PR, Mazumdar S, Butters MA, Stack JA, Schlernitzauer MA, Whyte EM, Gildengers A, Karp J, Lenze E, Szanto K, Bensasi S, Kupfer DJ: Maintenance treatment of major depression in old age.  N Engl J Med 2006; 354: 1130— 1138
[PubMed]
[CrossRef]
 
References Container
Dietz PM, Williams SB, Callaghan WM, Bachman DJ, Whitlock EP, Hornbrook MC: Clinically identified maternal depression before, during, and after pregnancies ending in live births.  Am J Psychiatry 2007; 164: 1515— 1520
[PubMed]
[CrossRef]
 
Cohen LS, Altshuler LL, Harlow BL, Nonacs R, Newport DJ, Viguera AC, Suri R, Burt VK, Hendrick V, Reminick AM, Loughead A, Vitonis AF, Stowe ZN: Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment.  JAMA 2006; 295: 499— 507
[PubMed]
[CrossRef]
 
Oberlander TF, Warburton W, Misri S, Aghajanian J, Hertzman C: Neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitor antidepressants and maternal depression using population-based linked health data.  Arch Gen Psychiatry 2006; 63: 898— 906
[PubMed]
[CrossRef]
 
References Container
Lesperance F, Frasure-Smith N, Koszycki D, Laliberte MA, Van Zyl LT, Baker B, Swenson JR, Ghatavi K, Abramson Bl, Dorian P, Guertin MC, CREATE Investigators: Effects of citalopram and interpersonal psychotherapy on depression in patients with coronary artery disease—the Canadian Cardiac Randomized Evaluation of Antidepressant and Psychotherapy Efficacy (CREATE) trial.  JAMA 2007; 297: 367— 379
[PubMed]
[CrossRef]
 
Evans DL, Charney DS, Lewis L, Golden RN, Gorman JM, Krishnan KR, Nemeroff CB, Bremner JD, Carney RM, Coyne JC, Delong MR, Frasure-Smith N, Glassman AH, Gold PW, Grant I, Gwyther L, Ironson G, Johnson RL, Kanner AM, Katon WJ, Kaufmann PG, Keefe FJ, Ketter T, Laughren TP, Leserman J, Lyketsos CG, McDonald WM, McEwen BS, Miller AH, Musselman D, O'Connor C, Petitto JM, Pollock BG, Robinson RG, Roose SP, Rowland J, Sheline Y, Sheps DS, Simon G, Spiegel D, Stunkard A, Sunderland T, Tibbits P Jr, Valvo WJ: Mood disorders in the medically ill: scientific review and recommendations.  Biol Psychiatry 2005; 58: 175— 189
[PubMed]
[CrossRef]
 
Taylor CB, Youngblood ME, Catellier D, Veith RC, Carney RM, Burg MM, Kaufmann PG, Shuster J, Mellman T, Blumenthal JA, Krishnan R, Jaffe AS, ENRICHD Investigators: Effects of antidepressant medication on morbidity and mortality in depressed patients after myocardial infarction.  Arch Gen Psychiatry 2005; 62: 792— 798
[PubMed]
[CrossRef]
 
Musselman DL, Evans DL, Nemeroff CB: The relationship of depression to cardiovascular disease: epidemiology, biology, and treatment.  Arch Gen Psychiatry 1998; 55: 580— 592
[PubMed]
[CrossRef]
 
Frasure-Smith N, Lesperance F, Talajic M: Depression following myocardial infarction: impact on 6-month survival.  JAMA 1993; 270: 1819— 1825
 
References Container
Rapaport MH, Clary C, Fayyad R, Endicott J: Quality-of-Life impairment in depressive and anxiety disorders.  Am J Psychiatry 2005; 162: 1171— 1178
[PubMed]
[CrossRef]
 
References Container
+

References

Irwin MR, Miller AH: Depressive disorders and immunity: 20 years of progress and discovery.  Brain Behav Immun 2007; 21: 374— 383
[PubMed]
[CrossRef]
 
Duman RS, Monteggia LM: A neurotrophic model for stress-related mood disorders.  Biol Psychiatry 2006; 59: 1116— 1127
[PubMed]
[CrossRef]
 
Merali Z, Du L, Hrdina P, Palkovits M, Faludi G, Poulter MO, Anisman H. Dysregulation in the suicide brain: mRNA expression of corticotropin-releasing hormone receptors and GABA(A) receptor subunits in frontal cortical brain region.  J Neurosci . 2004  2 11; 24( 6): 1478— 85. Free text at http://www.jneurosci.org/cgi/content/full/24/6/1478
[PubMed]
[CrossRef]
 
Vythilingam M, Heim C, Newport J, Miller AH, Anderson E, Bronen R, Brummer M, Staib L, Vermetten E, Charney DS, Nemeroff CB, Bremner JD: Childhood trauma associated with smaller hippocampal volume in women with major depression.  Am J Psychiatry 2002; 159: 2072— 2080
[PubMed]
[CrossRef]
 
Klimek V, Schenck JE, Han H, Stockmeier CA, Ordway GA. Dopaminergic abnormalities in amygdaloid nuclei in major depression: a postmortem study.  Biol Psychiatry . 2002  10 1; 52( 7): 740— 8.
[PubMed]
[CrossRef]
 
Hindmarch I: Expanding the horizons of depression: beyond the monoamine hypothesis.  Hum Psychopharmacol 2001; 16: 203— 218
[PubMed]
[CrossRef]
 
Manji HK, Duman RS: Impairments of neuroplasticity and cellular resilience in severe mood disorders: implications for the development of novel therapeutics.  Psychopharmacol Bull 2001; 35: 5— 49
 
McEwen BS, Magarinos AM: Stress and hippocampal plasticity: implications for the pathophysiology of affective disorders.  Hum Psychopharmacol 2001; 16: S7— S19
[PubMed]
[CrossRef]
 
Sapolsky RM: The possibility of neurotoxicity in the hippocampus in major depression: a primer on neuron death.  Biol Psychiatry 2000; 48: 755— 765
[PubMed]
[CrossRef]
 
Moreno FA, Gelenberg AJ, Heninger GR, Potter RL, McKnight KM, Allen J, Phillips AP, Delgado PL: Tryptophan depletion and depressive vulnerability.  Biol Psychiatry 1999; 46: 498— 505
[PubMed]
[CrossRef]
 
Mayberg HS, Liotti M, Brannan SK, McGinnis S, Mahurin RK, Jerabek PA, Silva JA, Tekell JL, Martin CC, Lancaster JL, Fox PT. Reciprocal limbic-cortical function and negative mood: converging PET findings in depression and normal sadness.  Am J Psychiatry . 1999  5; 156( 5): 675— 82.
[PubMed]
 
Musselman DL, Tomer A, Manatunga AK, Knight BT, Porter MR, Kasey S, Marzec U, Harker LA, Nemeroff CB. Exaggerated platelet reactivity in major depression.  Am J Psychiatry . 1996  10; 153( 10): 1313— 7.
[PubMed]
 
Coplan JD, Andrews W, Rosenblum LA, Owens MJ, Friedman S, Gorman JM, Nemeroff CB. Persistent elevations of cerebrospinal fluid concentrations of corticotropin-releasing factor in adult nonhuman primates exposed to early-life stressors: implications for the pathophysiology of mood and anxiety disorders.  Proc Natl Acad Sci USA . 1996  2 20; 93( 4): 1619— 23. Free text at http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pubmed&pubmedid=8643680
[PubMed]
[CrossRef]
 
DeBellis MD, Gold PW, Geracioti TD, Listwak SJ, Kling MA. Association of fluoxetine treatment with reductions in CSF concentrations of corticotropin-releasing hormone and arginine vasopressin in patients with major depression.  Am J Psychiatry 1993150: 656— 657
 
Nemeroff CB, Widerlöv E, Bissette G, Walléus H, Karlsson I, Eklund K, Kilts CD, Loosen PT, Vale W. Elevated concentrations of CSF corticotropin-releasing factor-like immunoreactivity in depressed patients.  Science . 1984  10 14; 226( 4680): 1342— 4.
[PubMed]
[CrossRef]
 
Checkley SA, Slade AP, Shur E. Growth hormone and other responses to clonidine in patients with endogenous depression.  Br J Psychiatry . 1981  1; 138: 51— 5.
 
References Container
Laje G, Paddock S, Manji H, Rush AJ, Wilson AF, Charney D, McMahon FJ: Genetic markers of suicidal ideation emerging during citalopram treatment of major depression.  Am J Psychiatry 2007; 164: 1530— 1538
[PubMed]
[CrossRef]
 
Hariri AR, Brown SM: Serotonin.  Am J Psychiatry 2006; 163: 12
[PubMed]
[CrossRef]
 
Kaufman J, Yang BZ, Douglas-Palumberi H, Grasso D, Lipschitz D, Houshyar S, Krystal JH, Gelernter J: Brain-derived neurotrophic factor-5-HTTLPR gene interactions and environmental modifiers of depression in children.  Biol Psychiatry 2007; 59: 673— 680
 
Kendler KS, Gatz M, Gardner CO, Pedersen NL: A Swedish national twin study of lifetime major depression.  Am J Psychiatry 2006; 163: 109— 114
[PubMed]
[CrossRef]
 
Kendler KS, Gardner CO, Prescott CA: Toward a comprehensive developmental model for major depression in men.  Am J Psychiatry 2006; 163: 115— 124
[PubMed]
[CrossRef]
 
McMahon FJ, Buervenich S, Charney D, Lipsky R, Rush AJ, Wilson AF, Sorant AJ, Papanicolaou GJ, Laje G, Fava M, Trivedi MH, Wisniewski SR, Manji H: Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment.  Am J Hum Genet 2006; 78: 804— 814
[PubMed]
[CrossRef]
 
Wilhelm K, Mitchell PB, Niven H, Finch A, Wedgwood L, Scimone A, Blair IP, Parker G, Schofield PR: Life events, first depression onset and the serotonin transporter gene.  Br J Psychiatry 2006; 188: 210— 215
[PubMed]
[CrossRef]
 
Gillespie NA, Whitfield JB, Williams B, Heath AC, Martin NG: The relationship between stressful life events, the serotonin transporter (5-HTTLPR) genotype and major depression.  Psychol Med 2005; 35: 101— 111
[PubMed]
[CrossRef]
 
Hariri AR, Drabant EM, Munoz KE, Kolachana BS, Mattay VS, Egan MF, Weinberger DR: A susceptibility gene for affective disorders and the response of the human amygdala.  Arch Gen Psychiatry 2005; 62: 146— 152
[PubMed]
[CrossRef]
 
Kendler KS, Kuhn JW, Vittum J, Prescott CA, Riley B: The interaction of stressful life events and a serotonin transporter polymorphism in the prediction of episodes of major depression—a replication.  Arch Gen Psychiatry 2005; 62: 529— 535
[PubMed]
[CrossRef]
 
Pezawas L, Meyer-Lindenberg A, Drabant EM, Verchinski BA, Munoz KE, Kolachana BS, Egan MF, Mattay VS, Hariri AR, Weinberger DR: 5-HTTLPR polymorphism impacts human cingulate-amygdala interactions: a genetic susceptibility mechanism for depression.  Nat Neurosci 2005; 8: 828— 834
[PubMed]
[CrossRef]
 
Weissman M, Wickramaratne P, Nomura Y, Warner V, Verdeli H, Pilowsky DJ, Grillon C, Bruder G: Families at high and low risk for depression—a 3-generation study.  Arch Gen Psychiatry 2005; 62: 29— 36
[PubMed]
[CrossRef]
 
Caspi A, Sugden K, Moffitt TE, Taylor A, Craig IW, Harrington H, McClay J, Mill J, MartinJ, Braithwaite A, Poulton R: Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene.  Science 2003; 301: 291— 293[Focus 2005; 3:156—160]
[PubMed]
 
Duman RS, Heninger GR, Nestler EJ: A molecular and cellular theory of depression.  Arch Gen Psychiatry 1997; 54: 597— 606
[PubMed]
 
References Container
Frank E, Kupfer DJ, Buysse DJ, Swartz HA, Pilkonis PA, Houck PR, Rucci P, Novick DM, Grochocinski VJ, Stapf DM: Randomized trial of weekly, twice-monthly, and monthly interpersonal psychotherapy as maintenance treatment for women with recurrent depression.  Am J Psychiatry 2007; 164: 761— 767
[PubMed]
[CrossRef]
 
Elkin I, Falconnier L, Martinovich Z, Mahoney C: Therapist effects in the National Institute of Mental Health Treatment of Depression Collaborative Research Program.  Psychother Res 2006; 16: 144— 160
[CrossRef]
 
Kim DM, Wampold BE, Bolt DM: Therapist effects in psychotherapy: a random-effects modeling of the National Institute of Mental Health Treatment of Depression Collaborative Research Program data.  Psychother Res 2006; 16: 161— 172
[CrossRef]
 
Beck AT: The current status of cognitive therapy: a 40-year retrospective.  Arch Gen Psychiatry 62: 953— 959, 2005
[PubMed]
[CrossRef]
 
Klein DN, Santiago NJ, Vivian D, Blalock JA, Kocsis JH, Markowitz JC, McCullough JP Jr, Rush AJ, Trivedi MH, Arnow BA, Dunner DL, Manber R, Rothbaum B, Thase ME, Keitner GI, Miller IW, Keller MB: Cognitive-behavioral analysis system of psychotherapy as a maintenance treatment for chronic depression.  J Consult Clin Psychol 2004; 72: 681— 688
[PubMed]
[CrossRef]
 
Berman RM, Marcus RN, Swanink R, McQuade RD, Carson WH, Corey-Lisle PK, Khan A: The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: A multicenter, randomized, double-blind placebo-controlled study.  J Clin Psychiatry 2007; 68: 843— 853
[PubMed]
[CrossRef]
 
McGrath PJ, Stewart JW, Quitkin FM, Chen Y, Alpert JE, Nierenberg AA, Fava M, Cheng J, Petkova E: Predictors of relapse in a prospective study of fluoxetine treatment of major depression.  Am J Psychiatry 2006; 163: 1542— 1548
[PubMed]
[CrossRef]
 
Olfson M, Marcus SC, Tedeschi M, Wan GJ: Continuity of antidepressant treatment for adults with depression in the United States.  Am J Psychiatry 2006; 163: 101— 108
[PubMed]
[CrossRef]
 
Rapaport MH, Gharabawi GM, Canuso CM, Mahmoud RA, Keller MB, Bossie CA, Turkoz I, Lasser RA, Loescher A, Bouhours P, Dunbar F, Nemeroff CB: Effects of risperidone augmentation in patients with treatment-resistant depression: results of open-label treatment followed by double-blind continuation.  Neuropsychopharmacology 2006; 31: 2505— 2513
[PubMed]
[CrossRef]
 
Ruhé HG, Huyser J, Swinkels JA, Schene AH: Switching antidepressants after a first selective serotonin reuptake inhibitor in major depressive disorder: A systematic review.  J Clin Psychiatry 2006; 67: 1836— 1855
[PubMed]
[CrossRef]
 
Thase ME: The failure of evidence-based medicine to guide treatment of antidepressant nonresponders.  J Clin Psychiatry 2006; 67: 1833— 1835
[PubMed]
[CrossRef]
 
Quitkin FM, McGrath PJ, Stewart JW, Deliyannides D, Taylor BP, Davies CA, Klein DF: Remission rates with 3 consecutive antidepressant trials: effectiveness for depressed outpatients.  J Clin Psychiatry 2005; 66: 670— 676
[PubMed]
[CrossRef]
 
Leichsenring F, Rabung S, Leibing E: The efficacy of short-term psychodynamic psychotherapy in specific psychiatric disorders.  Arch Gen Psychiatry 2004; 61: 1208— 1216
[PubMed]
[CrossRef]
 
Kennedy SH, Konarski JZ, Segal ZV, Lau MA, Bieling PJ, McIntyre RS, Mayberg HS: Differences in brain glucose metabolism between responders to CBT and venlafaxine in a 16-week randomized controlled trial.  Am J Psychiatry 2007; 164: 778— 788
[PubMed]
[CrossRef]
 
Zisook S, Lesser I, Stewart JW, Wisniewski SR, Balasubramani GK, Fava M, Gilmer WS, Dresselhaus TR, Thase ME, Nierenberg AA, Trivedi MH, Rush AJ: Effect of age at onset on the course of major depressive disorder.  Am J Psychiatry 2007; 164: 1539— 1546
[PubMed]
[CrossRef]
 
Dimidjian S, Hollon SD, Dobson KS, Schmaling KB, Kohlenberg RJ, Addis ME, Gallop R, McGlinchey JB, Markley DK, Gollan JK, Atkins DC, Dunner DL, Jacobson NS: Randomized trial of behavioral activation, cognitive therapy, and antidepressant medication in the acute treatment of adults with major depression.  J Consult Clin Psychol 2006; 74: 658— 670
[PubMed]
[CrossRef]
 
Markowitz JC, Kocsis JH, Bleiberg KL, Christos PJ, Sacks M: A comparative trial of psychotherapy and pharmacotherapy for "pure" dysthymic patients.  J Affect Disord 2005; 89: 167— 175
[PubMed]
[CrossRef]
 
March JS, Silva S, Petrycki S, Curry J, Wells K, Fairbank J, Burns B, Domino M, McNulty S, Vitiello B, Severe J: The Treatment for Adolescents With Depression Study (TADS): long-term effectiveness and safety outcomes.  Arch Gen Psychiatry 2007; 64: 1132— 1143
[PubMed]
[CrossRef]
 
Derubeis RJ, Hollon SD, Amsterdam JD, Shelton RC, Young PR, Salomon RM, O'Reardon JP, Lovett ML, Gladis MM, Brown LL, Gallop R: Cognitive therapy vs medications in the treatment of moderate to severe depression.  Arch Gen Psychiatry 2005; 62: 409— 416
[PubMed]
[CrossRef]
 
Fochtmann L, Gelenberg AJ: Guideline watch: practice guideline for the treatment of patients with major depressive disorder, 2nd edition.  Focus 2005; 3: 34— 42
 
Linde K, Berner M, Egger M, Mulrow C: St John's wort for depression—meta-analysis of randomised controlled trials.  Br J Psychiatry 2005; 186: 99— 107
[PubMed]
[CrossRef]
 
Keller MB, McCullough JP, Klein DN, Arnow B, Dunner DL, Gelenberg AJ, Markowitz JC, Nemeroff CB, Russell JM, Thase ME, Trivedi MH, Zajecka J: A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression.  N Engl J Med 2000; 342: 1462— 1470
[PubMed]
[CrossRef]
 
References Container
Thase ME, Friedman ES, Biggs MM, Wisniewski SR, Trivedi MH, Luther JF, Fava M, Nierenberg AA, McGrath PJ, Warden D, Niederehe G, Hollon SD, Rush AJ: Cognitive therapy versus medication in augmentation and switch strategies as second-step treatments: a STAR*D report.  Am J Psychiatry 2007; 164: 739— 752
[PubMed]
[CrossRef]
 
Wisniewski SR, Fava M, Trivedi MH, Thase ME, Warden D, Niederehe G, Friedman ES, Biggs MM, Sackeim HA, Shores-Wilson K, McGrath PJ, Lavori PW, Miyahara S, Rush AJ: Acceptability of second-step treatments to depressed outpatients: a STAR*D report.  Am J Psychiatry 2007; 164: 753— 760
[PubMed]
[CrossRef]
 
McGrath PJ, Stewart JW, Fava M, Trivedi MH, Wisniewski SR, Nierenberg AA, Thase ME, Davis L, Biggs MM, Shores-Wilson K, Luther JF, Niederehe G, Warden D, Rush AJ, Star*D Trial Team: Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medications trials for depression: A STAR*D report.  Am J Psychiatry 2006; 163: 1531— 1541
[PubMed]
[CrossRef]
 
Nierenberg AA, Fava M, Trivedi MH, Wisniewski SR, Thase ME, McGrath PJ, Alpert JE, Warden D, Luther JF, Niederehe G, Lebowitz B, Shores-Wison K, Rush AJ: A comparison of lithium and T3 augmentation following two failed medication treatments for depression: A STAR*D report.  Am J Psychiatry 2006; 163: 1519— 1530
[PubMed]
[CrossRef]
 
Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, Niederehe G, Thase ME, Lavori PW, Lebowitz BD, McGrath PJ, Rosenbaum JF, Sackeim HA, Kupfer DJ, Luther J, Fava M: Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a Star*D report.  Am J Psychiatry 2006; 163: 1905— 1917
[PubMed]
[CrossRef]
 
Rush AJ, Trivedi MH, Wisniewski SR, Stewart JW, Nierenberg AA, Thase ME, Ritz L, Biggs M, Warden D, Luther JF, Shores-Wilson K, Niederehe G, Fava M, STAR*D Study Team: Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression.  N Engl J Med 2006; 354: 1231— 1242
[PubMed]
[CrossRef]
 
Trivedi MH, Fava M, Wisniewski SR, Thase ME, Quitkin F, Warden D, Ritz L, Nierenberg AA, Lebowitz BD, Biggs MM, Luther JF, Shores-Wilson K, Rush AJ, Star*D Study Team: Medication augmentation after the failure of SSRIs for depression.  N Engl J Med 2006; 354: 1243— 1252
[PubMed]
[CrossRef]
 
Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, Norquist G, Howland RH, Lebowitz B, Mcgrath PJ, Shores-Wilson K, Biggs MM, Balasubramani GK, Fava M, Star*D Study Team: Evaluation of outcomes with citalopram for depression using measurement-based care in Star*D: implications for clinical practice.  Am J Psychiatry 2006; 163: 28— 40
[PubMed]
[CrossRef]
 
Weissman MM, Pilowsky DJ, Wickramaratne PJ, Talati A, Wisniewski SR, Fava M, Hughes CW, Garber J, Malloy E, King CA, Cerda G, Sood AB, Alpert JE, Trivedi MH, Rush AJ, STAR*D-Child Team: Remissions in maternal depression and child psychopathology: a STAR*D-child report.  JAMA 2006; 295: 1389— 1398
[PubMed]
[CrossRef]
 
Fava M, Rush AJ, Wisneiweski SR, Nierenberg AA, Alpert JE, McGrath PJ, Thase ME, Warden D, Biggs M, Luther JF, Niederehe G, Ritz L, Trivedi MH: A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: a STAR*D report.  Am J Psychiatry 2006; 163: 1521— 1541
 
References Container
Brent D: Antidepressants and suicidal behavior: cause or cure?  Am J Psychiatry 2007; 164: 989— 991
[PubMed]
[CrossRef]
 
Posner K, Oquendo MA, Gould M, Stanley B, Davies M: Columbia Classification Algorithm of Suicide Assessment (C-CASA): classification of suicidal events in the FDA's pediatric suicidal risk analysis of antidepressants.  Am J Psychiatry 2007; 164: 1035— 1043
[PubMed]
[CrossRef]
 
Sakinofsky I: Suicidality in depressive illness. Part I: current controversies.  Can J Psychiatry 2007; 52( 6Suppl 1): 71S— 84S. Available online at http://publications.cpa-apc.org/media.php?mid=425
[PubMed]
 
Simon GE, Savarino J: Suicide attempts among patients starting depression treatment with medications or psychotherapy.  Am J Psychiatry 2007; 164: 1029— 1034.
 
Szanto K, Mulsant BH, Houck PR, Dew MA, Dombrovski A, Pollock BG, Reynolds CF 3rd: Emergence, persistence, and resolution of suicidal ideation during treatment of depression in old age.  J Affect Disord 2007; 98: 153— 161
[PubMed]
[CrossRef]
 
Isacsson J: Depression is the core of suicidality—its treatment is the cure.  Acta Psychiatr Scand 2006; 114: 149— 150
[PubMed]
[CrossRef]
 
Gibbons RD, Hur K, Bhaumik KL, Mann J: The relationship between antidepressant medication use and rate of suicide.  Arch Gen Psychiatry 2005; 62: 165— 171
[PubMed]
[CrossRef]
 
Mann J, Apter A, Bertolote J, Beautrais A, Currier D, Haas A, Hegerl U, Lonnqvist J, Malone K, Marusic A, Mehlum L, Patton G, Phillips M, Rutz W, Rihmer Z, Schmidtke A, Shaffer D, Silverman M, Takahashi Y, Varnik A, Wasserman D, Yip P, Hendin H: Suicide prevention strategies: a systematic review.  JAMA 2005; 294: 2064— 2074
[PubMed]
[CrossRef]
 
Martinez C, Rietbrock S, Wise L, Ashby D, Chick J, Moseley J, Evans S, Gunnell D: Antidepressant treatment and the risk of fatal and non-fatal self harm in first episode depression: nested case-control study.  Br Med J 2005; 330: 389— 393
[CrossRef]
 
References Container
Fenton L, Fasula M, Ostroff, R, Sanacora G: Can cognitive behavioral therapy reduce relapse rates of depression after ECT? A preliminary study.  J ECT 2006; 22: 196— 198
[PubMed]
[CrossRef]
 
Couturier JL: Efficacy of rapid-rate repetitive transcranial magnetic stimulation in the treatment of depression: a systematic review and meta-analysis.  J Psychiatry Neurosci 2005; 30: 83— 90
[PubMed]
 
Dunn AL, Trivedi MH, Kampert JB, Clark CG, Chambliss HO: Exercise treatment for depression—efficacy and dose response.  Am J Prev Med 2005; 28: 1— 8
 
Rush AJ, Marangell LB, Sackeim HA, George MS, Brannan SK, Davis SM, Howland R, Kling MA, Rittberg BR, Burke WJ, Rapaport MH, Zajecka J, Nierenberg AA, Husain MM, Ginsberg D, Cooke RG: Vagus nerve stimulation for treatment-resistant depression: a randomized, controlled acute phase trial.  Biol Psychiatry 2005; 58: 347— 354
[PubMed]
[CrossRef]
 
Rush AJ, Sackeim HA, Marangell LB, George MS, Brannan SK, Davis SM, Lavori P, Howland R, Kling MA, Rittberg B, Carpenter L, Ninan P, Moreno F, Schwartz T, Conway C, Burke M, Barry JJ: Effects of 12 months of vagus nerve stimulation in treatment-resistant depression: a naturalistic study.  Biol Psychiatry 2005; 58: 355— 363
[PubMed]
[CrossRef]
 
Mayberg HS, Lozano AM, Voon V, Mcneely HE, Seminowicz D, Hamani C, Schwalb JM, Kennedy SH: Deep brain stimulation for treatment-resistant depression.  Neuron 2005; 45: 651— 660
[PubMed]
[CrossRef]
 
Pagnin D, de Queiroz V, Pini S, Cassano GB: Efficacy of ECT in depression: a meta-analytic review.  J ECT 2004; 20: 13— 20
[PubMed]
[CrossRef]
 
Kho KH, van Vreeswijk MF, Simpson S, Zwinderman AH: A meta-analysis of electroconvulsive therapy efficacy in depression.  J ECT 2003; 19: 139— 147
[PubMed]
[CrossRef]
 
References Container
Dew MA, Whyte EM, Lenze EJ, Houck PR, Mulsant BH, Pollock BG, Stack JA, Bensasi S, Reynolds CF: Recovery from major depression in older adults receiving augmentation of antidepressant pharmacotherapy.  Am J Psychiatry 2007; 164: 892— 899
[PubMed]
[CrossRef]
 
Reynolds CF 3rd, Dew MA, Pollock BG, Mulsant BH, Frank E, Miller MD, Houck PR, Mazumdar S, Butters MA, Stack JA, Schlernitzauer MA, Whyte EM, Gildengers A, Karp J, Lenze E, Szanto K, Bensasi S, Kupfer DJ: Maintenance treatment of major depression in old age.  N Engl J Med 2006; 354: 1130— 1138
[PubMed]
[CrossRef]
 
References Container
Dietz PM, Williams SB, Callaghan WM, Bachman DJ, Whitlock EP, Hornbrook MC: Clinically identified maternal depression before, during, and after pregnancies ending in live births.  Am J Psychiatry 2007; 164: 1515— 1520
[PubMed]
[CrossRef]
 
Cohen LS, Altshuler LL, Harlow BL, Nonacs R, Newport DJ, Viguera AC, Suri R, Burt VK, Hendrick V, Reminick AM, Loughead A, Vitonis AF, Stowe ZN: Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment.  JAMA 2006; 295: 499— 507
[PubMed]
[CrossRef]
 
Oberlander TF, Warburton W, Misri S, Aghajanian J, Hertzman C: Neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitor antidepressants and maternal depression using population-based linked health data.  Arch Gen Psychiatry 2006; 63: 898— 906
[PubMed]
[CrossRef]
 
References Container
Lesperance F, Frasure-Smith N, Koszycki D, Laliberte MA, Van Zyl LT, Baker B, Swenson JR, Ghatavi K, Abramson Bl, Dorian P, Guertin MC, CREATE Investigators: Effects of citalopram and interpersonal psychotherapy on depression in patients with coronary artery disease—the Canadian Cardiac Randomized Evaluation of Antidepressant and Psychotherapy Efficacy (CREATE) trial.  JAMA 2007; 297: 367— 379
[PubMed]
[CrossRef]
 
Evans DL, Charney DS, Lewis L, Golden RN, Gorman JM, Krishnan KR, Nemeroff CB, Bremner JD, Carney RM, Coyne JC, Delong MR, Frasure-Smith N, Glassman AH, Gold PW, Grant I, Gwyther L, Ironson G, Johnson RL, Kanner AM, Katon WJ, Kaufmann PG, Keefe FJ, Ketter T, Laughren TP, Leserman J, Lyketsos CG, McDonald WM, McEwen BS, Miller AH, Musselman D, O'Connor C, Petitto JM, Pollock BG, Robinson RG, Roose SP, Rowland J, Sheline Y, Sheps DS, Simon G, Spiegel D, Stunkard A, Sunderland T, Tibbits P Jr, Valvo WJ: Mood disorders in the medically ill: scientific review and recommendations.  Biol Psychiatry 2005; 58: 175— 189
[PubMed]
[CrossRef]
 
Taylor CB, Youngblood ME, Catellier D, Veith RC, Carney RM, Burg MM, Kaufmann PG, Shuster J, Mellman T, Blumenthal JA, Krishnan R, Jaffe AS, ENRICHD Investigators: Effects of antidepressant medication on morbidity and mortality in depressed patients after myocardial infarction.  Arch Gen Psychiatry 2005; 62: 792— 798
[PubMed]
[CrossRef]
 
Musselman DL, Evans DL, Nemeroff CB: The relationship of depression to cardiovascular disease: epidemiology, biology, and treatment.  Arch Gen Psychiatry 1998; 55: 580— 592
[PubMed]
[CrossRef]
 
Frasure-Smith N, Lesperance F, Talajic M: Depression following myocardial infarction: impact on 6-month survival.  JAMA 1993; 270: 1819— 1825
 
References Container
Rapaport MH, Clary C, Fayyad R, Endicott J: Quality-of-Life impairment in depressive and anxiety disorders.  Am J Psychiatry 2005; 162: 1171— 1178
[PubMed]
[CrossRef]
 
References Container
+
+

CME Activity

There is currently no quiz available for this resource. Please click here to go to the CME page to find another.
Submit a Comments
Please read the other comments before you post yours. Contributors must reveal any conflict of interest.
Comments are moderated and will appear on the site at the discertion of APA editorial staff.

* = Required Field
(if multiple authors, separate names by comma)
Example: John Doe



Related Content
Articles
Books
DSM-5™ Clinical Cases > Chapter 4.  >
DSM-5™ Handbook of Differential Diagnosis > Chapter 2.  >
DSM-5™ Clinical Cases > Chapter 4.  >
The American Psychiatric Publishing Textbook of Psychopharmacology, 4th Edition > Chapter 45.  >
APA Practice Guidelines > Chapter 11.  >
Topic Collections
Psychiatric News
APA Guidelines
PubMed Articles